Delineation of prognostic biomarkers in prostate cancer

Saravana M. Dhanasekaran, Terrence R. Barrette, Debashis Ghosh, Rajal Shah, Sooryanarayana Varambally, Kotoku Kurachi, Kenneth J. Pienta, Mark A. Rubin, Arul M. Chinnaiyan

Research output: Contribution to journalArticle

1351 Scopus citations

Abstract

Prostate cancer is the most frequently diagnosed cancer in American men. Screening for prostate-specific antigen (PSA) has led to earlier detection of prostate cancer, but elevated serum PSA levels may be present in non-malignant conditions such as benign prostatic hyperlasia (BPH). Characterization of gene-expression profiles that molecularly distinguish prostatic neoplasms may identify genes involved in prostate carcinogenesis, elucidate clinical biomarkers, and lead to an improved classification of prostate cancer. Using microarrays of complementary DNA, we examined gene-expression profiles of more than 50 normal and neoplastic prostate specimens and three common prostate-cancer cell lines. Signature expression profiles of normal adjacent prostate (NAP), BPH, localized prostate cancer, and metastatic, hormone-refractory prostate cancer were determined. Here we establish many associations between genes and prostate cancer. We assessed two of these genes - Hepsin, a transmembrane serine protease, and pim-1, a serine/threonine kinase - At the protein level using tissue microarrays consisting of over 700 clinically stratified prostate-cancer specimens. Expression of hepsin and pim-1 proteins was significantly correlated with measures of clinical outcome. Thus, the integration of cDNA microarray, high-density tissue microarray, and linked clinical and pathology data is a powerful approach to molecular profiling of human cancer.

Original languageEnglish (US)
Pages (from-to)822-826
Number of pages5
JournalNature
Volume412
Issue number6849
DOIs
StatePublished - Aug 23 2001
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Delineation of prognostic biomarkers in prostate cancer'. Together they form a unique fingerprint.

Cite this